Ceptaris Therapeutics
Pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
Launch date
Employees
Market cap
-
Enterprise valuation
€227m (Public information from Jul 2013)
Malvern Iowa (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $750k | Series A | |
N/A | $500k | Early VC | |
$4.5m | Series B | ||
$14.5m | Series C | ||
N/A | $3.1m | Early VC | |
N/A | N/A | Early VC | |
N/A | $14.4m | Series D | |
$15.0m | Debt | ||
$10.0m | Series D | ||
$250m Valuation: $250m | Acquisition | ||
Total Funding | €43.4m |